Logo image of NEUE

NEUEHEALTH INC (NEUE) Stock Fundamental Analysis

NYSE:NEUE - New York Stock Exchange, Inc. - US10920V4041 - Common Stock - Currency: USD

7.35  -0.04 (-0.54%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NEUE. NEUE was compared to 108 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of NEUE have multiple concerns. NEUE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NEUE was profitable.
NEUE had a negative operating cash flow in the past year.
In the past 5 years NEUE always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: NEUE reported negative operating cash flow in multiple years.
NEUE Yearly Net Income VS EBIT VS OCF VS FCFNEUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 -500M -1B -1.5B -2B -2.5B

1.2 Ratios

With a Return On Assets value of -110.18%, NEUE is not doing good in the industry: 94.39% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -110.18%
ROE N/A
ROIC N/A
ROA(3y)-54.32%
ROA(5y)-38.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NEUE Yearly ROA, ROE, ROICNEUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 100 -100 200 -200 300

1.3 Margins

NEUE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NEUE Yearly Profit, Operating, Gross MarginsNEUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

More info and screens

3

2. Health

2.1 Basic Checks

NEUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
NEUE has more shares outstanding than it did 1 year ago.
The debt/assets ratio for NEUE is higher compared to a year ago.
NEUE Yearly Shares OutstandingNEUE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2M 4M 6M 8M
NEUE Yearly Total Debt VS Total AssetsNEUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 1B 2B 3B 4B

2.2 Solvency

Based on the Altman-Z score of -5.78, we must say that NEUE is in the distress zone and has some risk of bankruptcy.
NEUE has a Altman-Z score of -5.78. This is amonst the worse of the industry: NEUE underperforms 88.78% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.78
ROIC/WACCN/A
WACC9.63%
NEUE Yearly LT Debt VS Equity VS FCFNEUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 1B -1B -2B

2.3 Liquidity

NEUE has a Current Ratio of 3.45. This indicates that NEUE is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NEUE (3.45) is better than 89.72% of its industry peers.
NEUE has a Quick Ratio of 3.45. This indicates that NEUE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.45, NEUE belongs to the top of the industry, outperforming 89.72% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.45
Quick Ratio 3.45
NEUE Yearly Current Assets VS Current LiabilitesNEUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 102.44% over the past year.
NEUE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -51.87%.
Measured over the past years, NEUE shows a very strong growth in Revenue. The Revenue has been growing by 54.80% on average per year.
EPS 1Y (TTM)102.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.04%
Revenue 1Y (TTM)-51.87%
Revenue growth 3Y31.12%
Revenue growth 5Y54.8%
Sales Q2Q%-13.54%

3.2 Future

The Earnings Per Share is expected to decrease by -29.51% on average over the next years. This is quite bad
Based on estimates for the next years, NEUE will show a decrease in Revenue. The Revenue will decrease by -5.16% on average per year.
EPS Next Y-216.11%
EPS Next 2Y-38.28%
EPS Next 3Y-29.51%
EPS Next 5YN/A
Revenue Next Year-26.98%
Revenue Next 2Y-10.61%
Revenue Next 3Y-5.16%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
NEUE Yearly Revenue VS EstimatesNEUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2B 4B 6B
NEUE Yearly EPS VS EstimatesNEUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -50 -100

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

NEUE is valuated cheaply with a Price/Earnings ratio of 5.57.
Based on the Price/Earnings ratio, NEUE is valued cheaper than 98.13% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 29.63. NEUE is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for NEUE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 5.57
Fwd PE N/A
NEUE Price Earnings VS Forward Price EarningsNEUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NEUE Per share dataNEUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 100 -100 -200

4.3 Compensation for Growth

A cheap valuation may be justified as NEUE's earnings are expected to decrease with -29.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-38.28%
EPS Next 3Y-29.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NEUE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUEHEALTH INC

NYSE:NEUE (2/21/2025, 8:04:01 PM)

7.35

-0.04 (-0.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)02-26 2025-02-26/amc
Inst Owners54.57%
Inst Owner ChangeN/A
Ins Owners6.3%
Ins Owner Change22.11%
Market Cap60.93M
Analysts45
Price Target7.14 (-2.86%)
Short Float %0.26%
Short Ratio0.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-79.05%
Min EPS beat(2)-118.63%
Max EPS beat(2)-39.47%
EPS beat(4)1
Avg EPS beat(4)80.65%
Min EPS beat(4)-118.63%
Max EPS beat(4)572.52%
EPS beat(8)3
Avg EPS beat(8)33.15%
EPS beat(12)3
Avg EPS beat(12)-17.41%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.78%
Min Revenue beat(2)-12.25%
Max Revenue beat(2)-3.31%
Revenue beat(4)1
Avg Revenue beat(4)-5.35%
Min Revenue beat(4)-12.25%
Max Revenue beat(4)1.3%
Revenue beat(8)2
Avg Revenue beat(8)-13.77%
Revenue beat(12)2
Avg Revenue beat(12)-44.62%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-64.1%
PT rev (3m)-60.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-38.14%
EPS NY rev (3m)-38.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.35%
Valuation
Industry RankSector Rank
PE 5.57
Fwd PE N/A
P/S 0.06
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)1.32
EY17.96%
EPS(NY)-13.12
Fwd EYN/A
FCF(TTM)-251.03
FCFYN/A
OCF(TTM)-250.87
OCFYN/A
SpS124.65
BVpS-46.61
TBVpS-55.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -110.18%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.32%
ROA(5y)-38.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover1.15
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.22%
Cap/Sales 0.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.45
Quick Ratio 3.45
Altman-Z -5.78
F-Score2
WACC9.63%
ROIC/WACCN/A
Cap/Depr(3y)50.59%
Cap/Depr(5y)60.56%
Cap/Sales(3y)1.13%
Cap/Sales(5y)0.99%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)102.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.04%
EPS Next Y-216.11%
EPS Next 2Y-38.28%
EPS Next 3Y-29.51%
EPS Next 5YN/A
Revenue 1Y (TTM)-51.87%
Revenue growth 3Y31.12%
Revenue growth 5Y54.8%
Sales Q2Q%-13.54%
Revenue Next Year-26.98%
Revenue Next 2Y-10.61%
Revenue Next 3Y-5.16%
Revenue Next 5YN/A
EBIT growth 1Y59.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year103.59%
EBIT Next 3Y27.76%
EBIT Next 5YN/A
FCF growth 1Y-852.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-767.21%
OCF growth 3YN/A
OCF growth 5YN/A